To clarify whether plasma somatostatin affects thyrotropin secretion in critical illness, plasma somatostatin and thyrotropin responses to thyrotropin-releasing hormone were studied in forty-three critically ill patients. High somatostatin levels were associated with blunted thyrotropin secretion in critically ill patients. There was an inverse correlation between plasma somatostatin levels and the maximum increment of thyrotropin after stimulation by thyrotropin-releasing hormone. Decreased somatostatin and increased thyrotropin secretion before discharge from the intensive care unit were demonstrated in survivors. On the other hand, non-survivors maintained high somatostatin levels and had blunted thyrotropin secretion during their intensive care admission. These results suggest that high plasma somatostatin levels may play a role in the blunted thyrotropin secretion observed in critical illness.
BaueA.E., GuntherB., HartlW., AckenheilM., HebererG.Altered hormonal activity in severely ill patients after injury or sepsis.Arch Surg1984; 119: 1125–1132.
2.
VierhapperH., LaggerA., WaldhausW., Grubeck-LoebensteinB., KleinbergerG.Impaired secretion of TSH in critically ill patients with “Low T4-syndrome”.Acta Endocrinol1982; 101: 542–549.
3.
BeckerR.A., VaughanG.M., ZieglerM.G.. Hypermetabolic low triiodothyronine syndrome of burn injury.Crit Care Med1982; 10: 870–875.
4.
SumitaS., UjikeY., NamikiA., WatanabeH.. Suppression of thyrotropin response to thyrotropin-releasing hormone and its association with severity of critical illness.Crit Care Med1994; 22: 1603–1609.
5.
KapteinE.M., SpencerC.A., KamielM.B., NicoloffJ.T.Prolonged dopamine administration and thyroid hormone economy in normal and critically ill subjects.J Clin Endocrinol Metab1980; 51: 387–393.
6.
Van den BergG., de ZegherF., VlassellaersD., SchetzM.. Thyrotropin-releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations.Crit Care Med1996; 24: 590–595.
7.
WenzelK.W.Pharmacological interference with in vitro tests of thyroid function.Metabolism1981; 30: 717–732.
8.
DubuisJ.M., DayerJ.M., Seigrist-KaiserC.A., BurgerA.G.Human recombinant interleukin-1β decreased plasma thyroid hormone and thyroid stimulating hormone levels in rats.Endocrinology1988; 123: 2175–2181.
9.
van der PollT., RomijinJ.A., WiersingaR.W., SauerweinH.P.Tumor necrosis factor: A putative mediator of the sick euthyroid syndrome in man.J Clin Endocrinol Metab1990; 71: 1567–1569.
10.
PangX.U., HershmanJ.M., MirellC.J., PekaryA.E.Impairment of hypothalamic-pituitary-thyroid function in rats treated with human recombinant Tumor Necrosis Factor-a (cachectin).Endocrinology1989; 125: 76–79.
11.
WeekeJ., HansenA.P., LundK.Inhibition by somatostatin of basal levels of serum thyrotropin (TSH) in normal men.J Clin Endocrinol Metab1975; 41: 168–171.
12.
SilerT.M., YenS.S.C., ValeW., GuilleminR.Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor.J Clin Endocrinol Metab1974; 38: 742–745.
13.
LuckeC., HoffkenB., MuhlenA.The effect of somatostatin levels in patients with primary hypothyroidism.Clin Endocrinol Metab1975; 41: 1082–1084.
14.
PatelY.C., RaoK., ReichlinS.Somatostatin in human cerebrospinal fluid.N Engl J Med1977; 296: 529–533.
15.
PatelY.C., WheatleyT., Fitz-PatrickD., BrockG.A sensitive radioimmunoassay for immunoreactive somatostatin in extracted plasma: Measurement and characterization of portal and peripheral plasma in the rats.Endocrinology1980; 107: 306–313.
16.
TannenbaumG.S., LingN., BrazeauP.Somatostatin-28 is longer acting and more selective than somatostatin-14 on pituitary and pancreatic hormone release.Endocrinology1982; 111: 101–107.
17.
GorisR.J.A., te BoekhostT.P.A., NuytinckJ.K.S.. Multiple organ failure.Generalized autodestructive inflammation? Arch Surg1985; 120: 1109–1115.
18.
KnausW.A., DraperE.A., WagnerD.P., ZimmermanJ.E.APACHE II. A severity of disease classification system.Crit Care Med1985; 13: 818–829.
19.
ArimuraA., GordinA., ShallyA.V.Increases in basal and thyrotropin-releasing hormone-stimulated secretion of thyrotropin and the effect of triiodothyronine in rats passively immunized with antiserum to somatostatin.Fed Proc1976; 35: 782.
20.
SaitoH., SaitoS.Plasma somatostatin in normal subjects and in various diseases: Increased levels in somatostatin-producing tumors.Horm Metabol Res1982; 14: 71–76.
21.
PenmanE., WassJ.A.H., MedbakS.. Response of circulating immunoreactive somatostatin to nutritional stimuli in normal subjects.Gastroenterology1981; 81: 692–699.
22.
VinikA.I., LevittN.S., PimstoneB.L., WagnerL.Peripheral plasma somatostatin-like immunoreactive responses to insulin hypoglycaemia and a mixed meal in healthy subjects and in noninsulin-dependent maturity-onset diabetics.J Clin Endocrinol Metab1981; 52: 330–337.
23.
ColturiT.J., UngerR.H., FeldmanM.Role of circulating somatostatin in regulation of gastric acid secretion, and islet cell function. Studies in healthy subjects and duodenal ulcer patients.J Clin Invest1984; 74: 417–423.
24.
SchusdziarraV., HarrisV., ConlonJ.M., ArimuraA., UngerR.Pancreatic and gastric somatostatin release in response to intragastric and intraduodenal nutrients and HCI in the dog.J Clin Invest1978; 62: 509–518.
